Glucagon-Like Polypeptide-1 and Brain
| dc.contributor.author | Bakiner, Okan Sefa | |
| dc.contributor.author | Ozsahin, Akadli Kursad | |
| dc.date.accessioned | 2021-03-30T08:41:42Z | |
| dc.date.available | 2021-03-30T08:41:42Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 1301-2193 | en_US |
| dc.identifier.uri | http://www.turkjem.org/uploads/pdf/630008759403475.pdf | |
| dc.identifier.uri | http://hdl.handle.net/11727/5632 | |
| dc.description.abstract | Glucagon-like polypeptide-1 has specific effects on the central nervous system, including regulation of glucose metabolism, positive cardiovascular effects, slowing intestinal motility, immune modulation, and regulation of appetite and energy expenditure. Recently, positive effects of GLP-1 on brain energy utilization, inhibition and restoration of neurodegeneration, response to stress, and protection against ischemic neuron damage have been demonstrated. Herein, the effects of glucagon-like polypeptide-1 on the central nervous system will be discussed. | en_US |
| dc.language.iso | eng | en_US |
| dc.relation.isversionof | 10.25179/tjem.2020-77362 | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Glucagon-like polypeptide-1 | en_US |
| dc.subject | brain | en_US |
| dc.subject | central nervous system | en_US |
| dc.subject | neurodegeneration | en_US |
| dc.subject | stroke | en_US |
| dc.title | Glucagon-Like Polypeptide-1 and Brain | en_US |
| dc.type | review | en_US |
| dc.relation.journal | TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM | en_US |
| dc.identifier.volume | 24 | en_US |
| dc.identifier.issue | 4 | en_US |
| dc.identifier.startpage | 343 | en_US |
| dc.identifier.endpage | 355 | en_US |
| dc.identifier.wos | 000598121200014 | en_US |
| dc.identifier.scopus | 2-s2.0-85097505438 | en_US |
